Top Stories https://www.benzinga.com/views/taxonomy/term/138079 en Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week https://www.benzinga.com/markets/cannabis/19/01/13010761/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we <p>There were numerous political announcements shaping the industry last week, with a Michigan state board ruling that more than 60 medical cannabis dispensaries that had to close at the end of last year due to new regulations will be allowed to re-open until March 31, providing them time to become compliant; and Florida Governor Ron DeSantis pledging to end the ban on medical marijuana flowers in the state.</p> <p>&ldquo;We saw a lot of movement&nbsp;at the state level this week. Ohio began its first medical marijuana sales with five dispensaries... For such a conservative state, this is a big deal,&rdquo; Debra Borchard, CEO of Green Market Report, told Benzinga. &ldquo;Then New York, which has one of the most restrictive medical marijuana programs, <a href="https://www.benzinga.com/markets/cannabis/19/01/12988204/ny-gov-cuomo-vows-to-legalize-adult-use-cannabis">heard the governor say</a> he wanted to legalize adult use cannabis within 100 days. That doesn&#39;t mean dispensaries will be selling product anytime soon, but this is a big switch from someone who once said that marijuana was a gateway drug.&rdquo;</p> <p>On the markets front, talk was dominated by Benzinga&#39;s 2019 <strong><a href="https://www.benzingacannabisconference.com/">Cannabis Capital Conference</a></strong>, getting investors and companies from around the world together for one of the most interesting industry gatherings of the year. Here are a few stories on the event worth checking out:</p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/13001806/4-cannabis-investors-share-their-predictions-for-industrys-future">4 Cannabis Investors Share Their Predictions For Industry&#39;s Future</a></p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/12999014/the-rest-of-the-world-is-moving-very-quickly-cannabis-execs-tackle-g">&#39;The Rest Of The World Is Moving Very Quickly&#39;: Cannabis Execs Tackle Global Market Opportunity</a></p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/12995010/multistate-operators-respond-to-changing-cannabis-market">Multistate Operators Respond To Changing Cannabis Market</a></p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/13001879/how-ianthus-aurora-curaleaf-cannex-make-their-pitch-to-investors">How iAnthus, Aurora, CuraLeaf, Cannex Make Their Pitch To Investors</a></p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/13006087/it-pays-to-be-vertical-curaleaf-ceo-tells-cannabis-capital-conferenc">&#39;It Pays to be Vertical,&#39; Curaleaf CEO Tells Cannabis Capital Conference</a></p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/12999024/medipharm-labs-pure-global-cannabis-weekend-unlimited-plus-products-">MediPharm Labs, Pure Global Cannabis, Weekend Unlimited, Plus Products, Trulieve Make Elevator Pitches</a></p> <p>&bull; <a href="https://www.benzinga.com/markets/cannabis/19/01/12995125/its-our-turn-now-for-wealth-creation-ianthus-ceo-tells-cannabis-capi">&#39;It&#39;s Our Turn Now For Wealth Creation,&#39; iAnthus CEO Tells Cannabis Capital Conference</a></p> <h3><img alt="Description: https://ssl.gstatic.com/ui/v1/icons/mail/images/cleardot.gif" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABAQMAAAAl21bKAAAAA3NCSVQBAQF8LneCAAAABlBMVEX///8AAABVwtN+AAAAAXRSTlMAQObYZgAAAAFiS0dEAIgFHUgAAAAMY21QUEpDbXAwNzEyAAAAB09tt6UAAAAKSURBVBjTY2AAAAACAAGYY2zXAAAAAElFTkSuQmCC" style="height:3px; width:3px" /><strong>Marijuana Indexes &amp; ETFs</strong></h3> <p>Over the last five trading days, the <strong>United States Marijuana Index, </strong>which tracks most of the largest marijuana stocks in the U.S., inched down by 1.85 percent, while the <strong>North American Marijuana Index</strong>, which also includes Canadian stocks, declined by around 2.63 percent.</p> <p>Over the same period, the <strong>Horizons Marijuana Life Sciences Index ETF</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hmlsf#OTC">HMLSF</a>) (TSE:HMMJ) lost 0.81 percent, while the <strong>ETFMG Alternative Harvest ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>) appreciated by 0.78 percent. The <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) closed the period up by 2.89 percent.</p> <h3><strong>Stock Moves</strong></h3> <p>Here are some of the top marijuana stocks (market cap above $300 million) in U.S. exchanges and how the performed over the last five trading days:</p> <p>&bull; <strong>Acreage Holdings </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/acrgf#OTC">ACRGF</a>): up 5.55 percent</p> <p><strong>&bull; Aphria Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/apha#NYSE">APHA</a>): down 4.30 percent</p> <p><strong>&bull; Aurora Cannabis Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acb#NYSE">ACB</a>): down 2.58 percent</p> <p><strong>&bull; CannTrust Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnttf#OTC">CNTTF</a>): up 1.71 percent</p> <p><strong>&bull; Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>): up 13.93 percent</p> <p><strong>&bull; Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>): up 9.16 percent</p> <p>&bull; <strong>Curaleaf Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/curlf#OTC">CURLF</a>): down 7.23 percent</p> <p><strong>&bull; Green Organic Dutchman Holdings Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/tgodf#OTC">TGODF</a>):<strong> </strong>down 7.88 percent</p> <p><strong>&bull; Green Thumb Industries Inc </strong>(OTC: <a class="ticker" ...</p><p><a href=https://www.benzinga.com/markets/cannabis/19/01/13010761/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we alt=Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week>Full story available on Benzinga.com</a></p> ACB ACRGF ACRZF Alan Brochstein APHA Cannabis Cannabis ETF cannabis news Cannabis Stock Index cannabis stocks CGC CNTTF CRON CURLF Danny Moses Debra Borchardt GBLX Giadha Aguirre De Carcer Green Market Report GTBIF GWPH HMLSF HYYDF invest in marijuana ITHUF Jon Najarian KNHBF marijuana Marijuana ETF Marijuana Index Marijuana Money marijuana news marijuana stocks MJ MMNFF MRMD MRRCF NBEV News North American Marijuana Index OGRMF Pot Stocks SMG SPY TGODF Tim Seymour TLRY United States Marijuana Index Top Stories Markets Trading Ideas Interview ETFs General SPY US78462F1030 SMG US8101861065 CGC ITHUF CNTTF ACRZF GWPH OGRMF GBLX ACB MJ NBEV MRMD MRRCF HYYDF HMLSF CRON TGODF MMNFF TLRY US88688T1007 GTBIF KNHBF APHA CURLF ACRGF News Cannabis Top Stories Markets Trading Ideas Interview ETFs General Benzinga Mon, 21 Jan 2019 14:56:47 +0000 Javier Hasse 13010761 at https://www.benzinga.com Analysts Hold Stances On Atlassian Following A 'Ripper' Of A Quarter https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006929/analysts-hold-stances-on-atlassian-following-a-ripper-o <p>Team collaboration and productivity software provider <strong> Atlassian Corporation PLC </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/team#NASDAQ">TEAM</a>) <a href=" https://www.cnbc.com/2019/01/17/atlassian-earnings-q2-2019.html">reported </a> forecast-beating Q2 results last week. Here are how a few analysts reacted to the print.</p> <h3>JMP: Atlassian Embracing The Emerging Trend</h3> <p>Atlassian is capitalizing on the trend of cloud adoption that is vesting the responsibility for maintaining quality, reliability and security of cloud offerings with developers, JMP Securities analyst Patrick Walravens said in a note. The analyst said the company is moving aggressively into the $20 billion IT operations and service management space, currently dominated by <strong>ServiceNow Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/now#NYSE">NOW</a>).</p> <p>The analyst termed Q3 guidance a bit muted, relative to the solid Q2 beat, given the company&#39;s plan to expand organic headcount, increase salaries and continue investment in its cloud infrastructure. As such, JMP raised its EPS estimates for FY2019 and FY2020.</p> <p>Walravens maintained a Market Perform rating on shares.</p> <h3>Raymond James: Atlassian Shares Fairly ...</h3><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006929/analysts-hold-stances-on-atlassian-following-a-ripper-o alt=Analysts Hold Stances On Atlassian Following A &#039;Ripper&#039; Of A Quarter>Full story available on Benzinga.com</a></p> Analyst Color DA Davidson Earnings JMP Securities Michael Turits News NOW Patrick Walravens Raymond James Rishi Jaluria TEAM Guidance Price Target Reiteration Top Stories Analyst Ratings NOW TEAM News Analyst Color Earnings Guidance Price Target Reiteration Top Stories Analyst Ratings Benzinga Mon, 21 Jan 2019 14:40:06 +0000 Shanthi Rexaline 13006929 at https://www.benzinga.com Domino's Hosted A Pizza Party With Investors—Here Are The Takeaways https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13007247/dominos-hosted-a-pizza-party-with-investors-here-are-th <p><strong>Domino&#39;s Pizza, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dpz#NYSE">DPZ</a>) hosted analysts for an <a href="https://www.nrn.com/quick-service/domino-s-plans-grow-size-60-percent-next-six-years">investor day presentation</a> where management discussed its position in the restaurant market and its outlook. Here is a summary of what some of the Street&#39;s top analysts said after the event.</p> <h3>The Analysts</h3> <ul> <li>UBS&#39; Dennis Geiger maintains a Neutral rating on Domino&#39;s Pizza with an unchanged $825 price target.</li> <li>BTIG Research&#39;s Peter Saleh maintains at Buy, price target lifted from $310 to $335.</li> <li>Wells Fargo&#39;s Jon Tower maintains at Market Weight, price target lifted from $230 to $238.</li> <li>Stephens&#39; Will Slabaugh maintains at Overweight, unchanged $310 price target.</li> </ul> <p>The stock closed Friday at $267.46, up 3.3&nbsp;percent.</p> <h3>UBS: Key Takeaways</h3> <p>The management team said it&#39;s looking to become the &quot;dominant number one&quot; global pizza brand, Geiger said in a research report. In terms of financial goals, management maintained its three- to five-year outlook of 3-6 percent U.S. and international same-store sales growth, 6-8 percent global unit growth and 8-12 percent total retail sales growth.</p> <p>Management also detailed a &quot;fortressing strategy&quot; of building new stores that are ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13007247/dominos-hosted-a-pizza-party-with-investors-here-are-th alt=Domino&#039;s Hosted A Pizza Party With Investors—Here Are The Takeaways>Full story available on Benzinga.com</a></p> Analyst Color BTIG Research Dennis Geiger DPZ Jon Tower Peter Saleh Pizza Pizza Delivery Stephens UBS Wells Fargo Will Slabaugh Price Target Restaurants Top Stories Analyst Ratings General DPZ US25754A2015 Analyst Color Price Target Restaurants Top Stories Analyst Ratings General Benzinga Sun, 20 Jan 2019 17:16:26 +0000 Jayson Derrick 13007247 at https://www.benzinga.com A Positive Prognosis For Health Care ETFs https://www.benzinga.com/general/biotech/19/01/13010523/a-positive-prognosis-for-health-care-etfs <p>Health care, the second-largest sector weight in the S&amp;P 500 behind technology, was one of just three sectors to post positive returns last year. As measured by the <strong>Health Care Select Sector SPDR</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xlv#NYSE">XLV</a>), the largest exchange traded fund dedicated to health care stocks, the sector is off to an impressive start in 2019; XLV is up nearly 3 percent this year.</p> <h3>What Happened</h3> <p>XLV and rival health care ETFs proved resilient last year as growth and momentum sectors fell out of favor with investors. The fund gained 6.3&nbsp;percent last year while its technology counterpart lost 1.7 percent. While health care is widely viewed as a defensive sector, its 2019 earnings growth is expected to be solid.</p> <p>&ldquo;While analysts have downgraded S&amp;P 500&reg; ...</p><p><a href=https://www.benzinga.com/general/biotech/19/01/13010523/a-positive-prognosis-for-health-care-etfs alt=A Positive Prognosis For Health Care ETFs>Full story available on Benzinga.com</a></p> Biotech Long Ideas Sector ETFs State Street XLV Health Care Top Stories Trading Ideas ETFs General XLV US81369Y2090 Long Ideas Sector ETFs Biotech Health Care Top Stories Trading Ideas ETFs General Benzinga Sun, 20 Jan 2019 17:01:12 +0000 ETF Professor 13010523 at https://www.benzinga.com Barron's Picks And Pans: Barrick Gold, Costco, Disney, GE And More https://www.benzinga.com/top-stories/19/01/13010489/barrons-picks-and-pans-barrick-gold-costco-disney-ge-and-more <ul> <li><em>This weekend&#39;s <a href="http://www.benzinga.com/topic/barron-s">Barron&#39;s</a> cover story features the top picks from the 2019 Barron&#39;s Roundtable.</em></li> <li><em>Other featured articles offer bargain gold mining stocks and how to play the life sciences boom.</em></li> <li><em>Also, the prospects for office REITs, a retail stock on sale and a battleground stock.</em></li> </ul> <p>&quot;<a href="https://www.barrons.com/articles/disney-dollar-tree-lockheed-martin-and-more-stock-picks-from-investment-experts-51547863018">Barron&#39;s 2019 Roundtable: What to Buy Now</a>&quot; by Lauren R. Rublin reveals what the 10 members of the Barron&#39;s 2019 Roundtable consider their best ideas for the coming year. Their picks include <strong>Walt Disney Co</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>) and <strong>Lockheed Martin Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmt#NYSE">LMT</a>). See what else made the list and why.</p> <p>Andrew Bary&#39;s &quot;<a href="https://www.barrons.com/articles/why-gold-mining-stocks-are-an-unalloyed-bargain-51547859601">Why Gold Mining Stocks Are an Unalloyed Bargain</a>&quot; points out that both <strong>Barrick Gold Corp</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gold#NYSE">GOLD</a>) and <strong>Newmont Mining Corp</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nem#NYSE">NEM</a>) have made big acquisitions. See why ...</p><p><a href=https://www.benzinga.com/top-stories/19/01/13010489/barrons-picks-and-pans-barrick-gold-costco-disney-ge-and-more alt=Barron&#039;s Picks And Pans: Barrick Gold, Costco, Disney, GE And More>Full story available on Benzinga.com</a></p> barrick gold Barron's Bio-Techne COST Costco DIS disney GE GE General Electric GOLD Kilroy Realty KRC LMT Lockheed Martin NEM newmont mining TECH walt disney Top Stories Media COST US22160K1051 GOLD US7523443098 TECH US8783771004 DIS US2546871060 GE US3696041033 KRC US49427F1084 LMT US5398301094 NEM US6516391066 Top Stories Media Benzinga Sat, 19 Jan 2019 18:00:44 +0000 Nelson Hem 13010489 at https://www.benzinga.com PG&E Bonds Won't Be In This Bond ETF Anytime Soon https://www.benzinga.com/trading-ideas/long-ideas/19/01/13004056/pg-e-bonds-wont-be-in-this-bond-etf-anytime-soon <p>Shares of <strong>PG&amp;E Corp.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pcg#NYSE">PCG</a>), the embattled California utility, have shed <a href="https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006477/analyst-cuts-pg-e-price-target-by-82-but-still-sees-som">a stunning 70 percent of their value</a> this year as the company is considering bankruptcy amid facing $30 billion in liabilities from the 2017 and 2018 California wildfires.</p> <p>The specter of bankruptcy and those wildfire claims prompted ratings agencies to slash PG&amp;E&#39;s corporate credit rating.</p> <h3>What To Know</h3> <p>A corporate credit rating that was once BBB- is now C, the really speculative end of the highly speculative junk bond ratings spectrum.</p> <p>While PG&amp;E bonds meet the definition of fallen angels, corporate bonds born with investment-grade ratings that are later downgrade to junk status, investors shouldn&#39;t expect to see the utility&#39;s debt appearing in the <strong>VanEck Vectors Fallen Angel High Yield Bond ETF</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/angl#NYSE">ANGL</a>) in the near-term.</p> <p>ANGL is the oldest and largest exchange traded ...</p><p><a href=https://www.benzinga.com/trading-ideas/long-ideas/19/01/13004056/pg-e-bonds-wont-be-in-this-bond-etf-anytime-soon alt=PG&amp;E Bonds Won&#039;t Be In This Bond ETF Anytime Soon>Full story available on Benzinga.com</a></p> ANGL Long Ideas PCG Bonds Specialty ETFs Top Stories Markets Trading Ideas ETFs PCG US69331C1080 ANGL Long Ideas Bonds Specialty ETFs Top Stories Markets Trading Ideas ETFs Benzinga Fri, 18 Jan 2019 20:04:28 +0000 ETF Professor 13004056 at https://www.benzinga.com Golf Equipment Sales Finally On The Upswing — What's Behind The Comeback? https://www.benzinga.com/news/19/01/12995089/golf-equipment-sales-finally-on-the-upswing-whats-behind-the-comeback <p>Golf is back, and that&#39;s not a reference to the 2019 PGA Tour.</p> <p>After years of<a href="https://www.marketwatch.com/story/death-watch-how-much-longer-can-golf-survive-2017-04-18"> doom and gloom in the industry</a>, golf has received some of the best news it a while short of Tiger Woods&#39; resurgence last year.</p> <p>After facing declines in the previous year, the U.S. golf retail business<a href="https://www.npd.com/wps/portal/npd/us/news/press-releases/2019/us-golf-market-sales-on-the-upswing-rising-8-percent-as-consumers-show-renewed-interest-in-spending-on-the-sport/#.XDzD2ylGB2A.twitter"> grew 8 percent</a> in the 12 months ending in November 2018&nbsp;to $2.6 billion, according to a new report from NPD Group.</p> <p>&ldquo;The macro environment for golf has been in a turbulent state, fueled by Golfsmith&rsquo;s bankruptcy, major brands cutting back on their golf business and courses closing. But today, we&rsquo;re starting to see normalization in the market as those deep holes are now being filled,&rdquo; said Matt Powell, NPD&#39;s vice president and senior sports industry advisor.</p> <p>&ldquo;Major sports retailers are now investing in golf to pick up some of the ...</p><p><a href=https://www.benzinga.com/news/19/01/12995089/golf-equipment-sales-finally-on-the-upswing-whats-behind-the-comeback alt=Golf Equipment Sales Finally On The Upswing — What&#039;s Behind The Comeback?>Full story available on Benzinga.com</a></p> David Abeles DISCA ELY GOLF Matt Powell NKE PGA of America PGA Tour Tiger Woods Torrey Pines Retail Sales Sports Top Stories Exclusives Interview General DISCA US25470F1049 GOLF ELY US1311931042 NKE US6541061031 Retail Sales Sports Top Stories Exclusives Interview General Benzinga Fri, 18 Jan 2019 18:25:37 +0000 Brett Hershman 12995089 at https://www.benzinga.com The Toy Story: After Weak Holidays, Hasbro Set for Rebound, Mattel Reliant on Barbie https://www.benzinga.com/analyst-ratings/price-target/19/01/13006806/the-toy-story-after-weak-holidays-hasbro-set-for-rebound <p>Big toy makers <strong>Hasbro Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/has#NASDAQ">HAS</a>) and <strong>Mattel, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mat#NASDAQ">MAT</a>) both finished 2018 below expectations, but there are bright spots for the coming year, particularly for Hasbro.</p> <p><strong>The Analyst</strong></p> <p>MKM&rsquo;s Eric Handler continues to have a Buy rating on Hasbro, but lowered his price target to $102 from $110, while lowering Q4 earnings estimates. Handler continues to have a Neutral rating on Mattel, with a $12 price target, down from $13.</p> <p><strong>The Thesis</strong></p> <p>Handler is more bullish on Hasbro, which he says is poised to bounce back in 2019 even after soft holidays.</p> <p>Investors should see above average growth in the new year, due to a combination of a strong product lineup, ongoing efficiencies and easing revenue headwinds, Handler said. He also said investors should benefit from a high single-digit dividend increase, ...</p><p><a href=https://www.benzinga.com/analyst-ratings/price-target/19/01/13006806/the-toy-story-after-weak-holidays-hasbro-set-for-rebound alt=The Toy Story: After Weak Holidays, Hasbro Set for Rebound, Mattel Reliant on Barbie>Full story available on Benzinga.com</a></p> American Girl Barbie Eric Handler Fisher Price HAS Hot Wheels MAT MKM Partners Price Target Top Stories Analyst Ratings HAS US4180561072 MAT US5770811025 Price Target Top Stories Analyst Ratings Benzinga Fri, 18 Jan 2019 17:55:35 +0000 Dave Royse 13006806 at https://www.benzinga.com CIBC Initiates Coverage On Cannabis Stocks, Sees Bright Future Ahead https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006914/cibc-initiates-coverage-on-cannabis-stocks-sees-bright- <p>Cannabis investors may be witnessing the rare birth of an<a href="https://www.benzingacannabisconference.com/"> entirely new industry</a>, and one Wall Street analyst said Friday three companies will emerge as the leaders of the new cannabis market.</p> <h3>The Analyst</h3> <p>CIBC analyst John Zamparo initiated coverage of the following three cannabis stocks:</p> <ul> <li><strong>Canopy Growth Corp</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>) initiated at Outperformer with a $65 price target.</li> <li><strong>Cronos Group Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>) initiated at Outperformer with a $22 price target.</li> <li><strong>Aphria Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/apha#NYSE">APHA</a>) initiated at Neutral with a $10 price target.</li> </ul> <h3>The Thesis</h3> <p>Typically, when a new industry emerges, such as the airline industry or the internet, a handful of companies ultimately end up dominating the lion&rsquo;s share of the market. ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006914/cibc-initiates-coverage-on-cannabis-stocks-sees-bright- alt=CIBC Initiates Coverage On Cannabis Stocks, Sees Bright Future Ahead>Full story available on Benzinga.com</a></p> Analyst Color APHA Cannabis CGC CIBC CRON John Zamparo MO STZ Price Target Initiation Top Stories Markets Analyst Ratings MO US02209S1033 STZ US21036P1084 CGC CRON APHA Analyst Color Cannabis Price Target Initiation Top Stories Markets Analyst Ratings Benzinga Fri, 18 Jan 2019 16:43:05 +0000 Wayne Duggan 13006914 at https://www.benzinga.com Analysts React After American Express Rings Up Q4 EPS, Sales Miss https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006704/analysts-react-after-american-express-rings-up-q4-eps-s <p><strong>American Express Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axp#NYSE">AXP</a>) reported Thursday with&nbsp;a fourth-quarter top-and-bottom-line miss.&nbsp;The credit card issuer guided to a better-than-expected&nbsp;revenue growth outlook for 2019, mostly due to a &quot;reasonably strong&quot; consumer. Here&#39;s how the Street reacted to the print.&nbsp;</p> <h3>The Analysts</h3> <ul> <li>Wells Fargo&#39;s Donald Fandetti maintains an Outperform rating on <a href="https://www.benzinga.com/stock/axp">American Express</a>&nbsp;with an unchanged $115 price target.</li> <li>RBC Capital Markets&#39; Jason Arnold maintains at Underperform, price target lifted from $91 to $95.</li> <li>Guggenheim Partners&#39; Jeff Cantwell maintains at Neutral.</li> <li>Argus Research Company&#39;s Stephen Biggar maintains at Hold.</li> </ul> <h3>Wells Fargo Sees Q4 &#39;Noise,&#39; Says Guidance &#39;Is Fine&#39;</h3> <p>American Express&#39; <a href="https://www.benzinga.com/pressreleases/19/01/b13002669/american-express-reports-fourth-quarter-earnings-per-share-of-2-32-and">Q4 report</a> included &quot;a lot of noise&quot; in the form of foreign exchange and tax woes,&nbsp;Fandetti said in a note.</p> <p>Proprietary billed business growth slowed from 12 percent in the third quarter to 10 percent &mdash; something that&nbsp;management&nbsp;attributed to difficult comps, but which could also be a function of global trade and other forms of volatility, the analyst said.&nbsp;</p> <p>Looking forward to 2019, AmEx&#39;s&nbsp;guidance &quot;is fine,&quot; with an EPS guide of $7.85 to $8.35 falling in-line ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006704/analysts-react-after-american-express-rings-up-q4-eps-s alt=Analysts React After American Express Rings Up Q4 EPS, Sales Miss>Full story available on Benzinga.com</a></p> Analyst Color Argus Research Company AXP credit cards Donald Fandetti Earnings Guggenheim Partners Jason Arnold Jeff Cantwell News payments RBC Capital Markets Stephen Biggar Wells Fargo Price Target Reiteration Top Stories Analyst Ratings AXP US0258161092 News Analyst Color Earnings Price Target Reiteration Top Stories Analyst Ratings Benzinga Fri, 18 Jan 2019 16:27:34 +0000 Jayson Derrick 13006704 at https://www.benzinga.com This Dividend ETF Quietly Grew In A Big Way In 2018 https://www.benzinga.com/trading-ideas/long-ideas/19/01/13004042/this-dividend-etf-quietly-grew-in-a-big-way-in-2018 <p>Some high dividend exchange traded funds were punished by the Federal Reserve&#39;s four interest rate hikes in 2018. Others posted impressive growth despite a challenging operating environment.</p> <p>That group includes the <strong>WBI Power Factor High Dividend ETF</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wbiy#NYSE">WBIY</a>).</p> <h3>What Happened</h3> <p>The WBI Power Factor High Dividend ETF has nearly $89 million in assets under management. As Paul Weisbruch, head of ETF sales and trading at Dallas-based <a href="http://www.espositosecurities.com/">Esposito Securities</a> points out, WBIY added $66 million in assets last year, an impressive haul considering many investors shied away from high dividend strategies as interest rates climbed.</p> <p>WBIY targets the Solactive Power Factor High Dividend Index and is just over two years old. The fund is ...</p><p><a href=https://www.benzinga.com/trading-ideas/long-ideas/19/01/13004042/this-dividend-etf-quietly-grew-in-a-big-way-in-2018 alt=This Dividend ETF Quietly Grew In A Big Way In 2018>Full story available on Benzinga.com</a></p> Long Ideas Paul Weisbruch WBIY Broad U.S. Equity ETFs Dividends Top Stories Trading Ideas ETFs WBIY Long Ideas Broad U.S. Equity ETFs Dividends Top Stories Trading Ideas ETFs Benzinga Fri, 18 Jan 2019 16:20:40 +0000 ETF Professor 13004042 at https://www.benzinga.com The Street Stays Bullish On Netflix Following Q4 Earnings https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006248/the-street-stays-bullish-on-netflix-following-q4-earnin <p>Streaming video giant <strong>Netflix, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>) reported its <a href="https://www.benzinga.com/news/earnings/19/01/13002820/netflix-shares-fall-on-mixed-q4-earnings">fourth-quarter results</a> highlighted by an earnings beat and a slight revenue miss, while domestic and international subscriber additions came in better than expected. The company guided its first-quarter EPS and revenue to be 56 cents and $4.49 billion, respectively, versus expectations of 82 cents per share and $4.61 billion.</p> <p>Here is a summary of how some of the Street&#39;s top analysts reacted to the print.</p> <h3>The Analysts</h3> <ul> <li>Bank of America&#39;s Nat Schindler maintains a Buy rating on Netflix with a price target lifted from $440 to $450.</li> <li>Goldman Sachs&#39; Heath Terry maintains at Buy (Conviction List), price target lifted from $420 to $450.</li> <li>Raymond James&#39; Justin Patterson maintains at Strong Buy, price target lifted from $450 to $470.</li> <li>KeyBanc Capital Markets&#39; Andy Hargreaves maintains at Sector Weight, no price target.</li> <li>Needham&#39;s Laura Martin maintains at Hold, no price target.</li> <li>Nomura&#39;s Mark Kelley maintains at Neutral, price target lifted from $300 to $320.</li> <li>Pivotal Research Group&#39;s Jeffrey Wlodarczak maintains at Buy, price target lifted from $480 to $500.</li> </ul> <p>The stock traded at $346.76 per share Friday morning. Shares are up about 50 percent since Dec. 24.</p> <h3>Bank Of America: Focus On Guidance</h3> <p>Management guided first-quarter paid net adds to be 8.9 million, which came in 6 percent ahead of what the Street had already modeled, Schindler said in a research note. The key focus on management&#39;s guidance is expectations to add 7.3 million international subscribers in the first quarter, which is 15 percent above expectations.</p> <p>The most impressive takeaway from the guidance is that operating margin should move from 9 percent at the start of 2019 and move above its 13 percent target this year and continue growing into 2020.</p> <p>Netflix&#39;s revenue ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/01/13006248/the-street-stays-bullish-on-netflix-following-q4-earnin alt=The Street Stays Bullish On Netflix Following Q4 Earnings>Full story available on Benzinga.com</a></p> Analyst Color Andy Hargreaves Bank of America Earnings Fortnite Gene Munster Goldman Sachs Heath Terry Jeffrey Wlodarczak Justin Patterson KeyBanc Capital Markets Laura Martin Loup Ventures Mark Kelley Nat Schindler Needham Netflix International Netflix Subscribers News NFLX Nomura Pivotal Research Group Raymond James Steve Van Sloun streaming video Guidance Price Target Top Stories Analyst Ratings Trading Ideas NFLX US64110L1061 News Analyst Color Earnings Guidance Price Target Top Stories Analyst Ratings Trading Ideas Benzinga Fri, 18 Jan 2019 14:40:33 +0000 Jayson Derrick 13006248 at https://www.benzinga.com Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year https://www.benzinga.com/general/biotech/19/01/12975729/searching-for-a-treatment-nash-investigational-drugs-with-catalysts-t <p>Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation of fat in the liver of people who do not consume alcohol.</p> <p>NAFLD is a less serious condition, although non-alcoholic steatohepatitis, or NASH &mdash; a&nbsp;subset of NAFLD &mdash; is life-threatening, given its potential to cause liver scarring and cirrhosis.</p> <p>NAFLD <a href="https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/symptoms-causes/syc-20354567"> affects </a> about 80-100 million people in the U.S. alone &mdash; roughly 25 percent of the total population.</p> <p><a href="https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8809488/a-primer-on-nash">NASH </a> affects about 30 million people in the U.S., or about 12 percent of the adults, according to National Institutes of Health estimates.</p> <p><em>See Also: <a href="https://www.benzinga.com/general/biotech/19/01/12943195/axsome-sage-therapeutics-move-on-positive-results-from-depression-dru"> Axsome, Sage Therapeutics Move On Positive Results From Depression Drug Studies </a></em></p> <h3>No Approved Drug&nbsp;</h3> <p>Notwithstanding the&nbsp;prevalence of the disorder, there is no FDA-approved therapy for NAFLD or NASH. Treatment options are available for improving the insulin resistance&nbsp;often found in NAFLD and NASH patients.</p> <p>Diagnosis of the disorder requires biopsy of the liver, which physicians do not want to do without a clear need. NASH is a silent killer that often does not manifest itself loudly enough for it to be diagnosed before it becomes lethal. Additionally, a lack of knowledge of the pathways that cause NAFLD is also a deterrent.</p> <h3>Potential Market Opportunity</h3> <p>NASH offers a $20 billion to $35 billion opportunity for companies developing drugs that target the condition, according to Biopharmadrive, which cited analyst estimates. The NASH biomarker market is estimated to reach $2.05 billion by 2025, according to&nbsp;<a href="https://www.grandviewresearch.com/press-release/global-non-alcoholic-steatohepatitis-nash-biomarkers-market">Grand View Research </a> estimates.</p> <p>A biomarker is a biologic feature used to measure the presence or progress of a disease or the ...</p><p><a href=https://www.benzinga.com/general/biotech/19/01/12975729/searching-for-a-treatment-nash-investigational-drugs-with-catalysts-t alt=Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year>Full story available on Benzinga.com</a></p> AGN Biopharmadrive Biotech fatty liver disease GILD GNFTF Grand View Research ICPT MDGL Non-alcoholic fatty liver disease Raymond James SRRK Steve Seedhouse VKTX Health Care Top Stories Trading Ideas General GILD US3755581036 AGN US0184901025 ICPT GNFTF VKTX MDGL SRRK Biotech Health Care Top Stories Trading Ideas General Benzinga Fri, 18 Jan 2019 14:15:37 +0000 Shanthi Rexaline 12975729 at https://www.benzinga.com High Times: The Marijuana ETF Soars To Start 2019 https://www.benzinga.com/markets/cannabis/19/01/13004607/high-times-the-marijuana-etf-soars-to-start-2019 <p>After slumping in the fourth quarter, the <strong>ETFMG Alternative Harvest ETF</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>), the only dedicated cannabis exchange traded fund listed in the United States, is off to a scintillating start in 2019.</p> <p>MJ is up 22.69 percent since the start of 2019, making it the best-performing non-leveraged ETF in January.</p> <h3>What To Know</h3> <p>Year-to-date, just 36 U.S.-listed ETFs are up at least 20 percent and MJ is the only member of that group that is not an inverse or leveraged fund. MJ slumped nearly 22 percent in 2018 with much of those losses contained to the fourth quarter despite a slew of positive post-Election Day news pertaining to increased legalization of <a href="https://www.benzingacannabisconference.com/">marijuana </a>across the U.S.</p> <p>MJ&#39;s rally to start 2019 has the ETF residing almost 6 percent above its 50-day ...</p><p><a href=https://www.benzinga.com/markets/cannabis/19/01/13004607/high-times-the-marijuana-etf-soars-to-start-2019 alt=High Times: The Marijuana ETF Soars To Start 2019>Full story available on Benzinga.com</a></p> ACB Cannabis CGC CRON Long Ideas MJ Sector ETFs TLRY Top Stories Markets Trading Ideas ETFs CGC ACB MJ CRON TLRY US88688T1007 Long Ideas Sector ETFs Cannabis Top Stories Markets Trading Ideas ETFs Benzinga Fri, 18 Jan 2019 13:24:42 +0000 ETF Professor 13004607 at https://www.benzinga.com Tesla Cuts 7% Of Workforce In Effort To Ramp Model 3 Production https://www.benzinga.com/news/19/01/13005615/tesla-cuts-7-of-workforce-in-effort-to-ramp-model-3-production <p><strong>Tesla Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) traded down Friday on <a href="https://www.wsj.com/articles/tesla-to-cut-workforce-by-7-11547805922">news</a>&nbsp;it will reduce its full-time workforce by 7 percent.</p> <h3><strong>What Happened</strong></h3> <p>CEO Elon Musk said the job cuts are intended to cut Model 3 production costs &mdash; and ultimately the final sales price to the promised, competitive $35,000.</p> <p>&quot;Tesla will need to make these cuts while increasing the Model 3 production rate and making many manufacturing engineering improvements in the coming months,&quot; Musk said in an internal email.</p> <h3><strong>Why It&rsquo;s Important</strong></h3> <p>Tesla has marketed the Model 3 as the most affordable electric vehicle on ...</p><p><a href=https://www.benzinga.com/news/19/01/13005615/tesla-cuts-7-of-workforce-in-effort-to-ramp-model-3-production alt=Tesla Cuts 7% Of Workforce In Effort To Ramp Model 3 Production>Full story available on Benzinga.com</a></p> Elon Musk Model 3 News TSLA Top Stories TSLA US88160R1014 News Top Stories Benzinga Fri, 18 Jan 2019 13:05:19 +0000 Elizabeth Balboa 13005615 at https://www.benzinga.com